Hunan Jingfeng Pharmaceutical Cash Flow-to-Debt Ratio
Hunan Jingfeng Pharmaceutical cash flow-to-debt ratio. Hunan Jingfeng Pharmaceutical (000908) has a Cash Flow-to-Debt Ratio of 0.14x as of September 2025, meaning its operating cash flow of CN¥125.78 Million could theoretically repay 0% of its total liabilities (CN¥915.74 Million) in one year. Check earnings quality score of Hunan Jingfeng Pharmaceutical to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hunan Jingfeng Pharmaceutical (1999–2024)
Cash flow-to-debt ratio of Hunan Jingfeng Pharmaceutical from 1999 to 2024. Historical debt coverage capacity for Hunan Jingfeng Pharmaceutical across 26 annual periods. Check Hunan Jingfeng Pharmaceutical cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Hunan Jingfeng Pharmaceutical Cash Flow-to-Debt Ratio by Year (1999–2024)
Hunan Jingfeng Pharmaceutical cash flow-to-debt ratio by year from 1999 to 2024. Year-by-year debt coverage analysis for Hunan Jingfeng Pharmaceutical. For the full cash flow conversion analysis, see 000908 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.01x | CN¥-5.55 Million | CN¥955.11 Million | ▼ -120.1% |
| 2023 | 0.03x | CN¥35.06 Million | CN¥1.21 Billion | ▼ -70.6% |
| 2022 | 0.10x | CN¥123.27 Million | CN¥1.25 Billion | ▲ +16.3% |
| 2021 | 0.08x | CN¥123.83 Million | CN¥1.46 Billion | ▲ +163.9% |
| 2020 | -0.13x | CN¥-271.68 Million | CN¥2.05 Billion | ▼ -981.6% |
| 2019 | 0.02x | CN¥36.17 Million | CN¥2.41 Billion | ▼ -89.9% |
| 2018 | 0.15x | CN¥350.94 Million | CN¥2.37 Billion | ▲ +122.0% |
| 2017 | 0.07x | CN¥151.65 Million | CN¥2.27 Billion | ▲ +1267.6% |
| 2016 | 0.00x | CN¥12.32 Million | CN¥2.52 Billion | ▼ -93.7% |
| 2015 | 0.08x | CN¥92.37 Million | CN¥1.19 Billion | ▼ -65.5% |
| 2014 | 0.22x | CN¥205.93 Million | CN¥919.76 Million | ▲ +2256.1% |
| 2013 | -0.01x | CN¥-3.44 Million | CN¥331.47 Million | ▼ -1371.2% |
| 2012 | 0.00x | CN¥351.50K | CN¥430.29 Million | ▲ +105.0% |
| 2011 | -0.02x | CN¥-6.87 Million | CN¥420.66 Million | ▲ +55.6% |
| 2010 | -0.04x | CN¥-15.21 Million | CN¥413.53 Million | ▼ -111.8% |
| 2009 | -0.02x | CN¥-11.88 Million | CN¥684.14 Million | ▼ -136.4% |
| 2008 | 0.05x | CN¥31.02 Million | CN¥650.60 Million | ▼ -56.5% |
| 2007 | 0.11x | CN¥52.26 Million | CN¥477.43 Million | ▼ -8.1% |
| 2006 | 0.12x | CN¥57.90 Million | CN¥486.08 Million | ▲ +202.2% |
| 2005 | -0.12x | CN¥-59.49 Million | CN¥510.48 Million | ▲ +59.0% |
| 2004 | -0.28x | CN¥-156.37 Million | CN¥550.11 Million | ▼ -811.7% |
| 2003 | 0.04x | CN¥22.51 Million | CN¥563.64 Million | ▼ -21.9% |
| 2002 | 0.05x | CN¥17.59 Million | CN¥343.98 Million | ▼ -79.5% |
| 2001 | 0.25x | CN¥30.50 Million | CN¥122.47 Million | ▲ +296.2% |
| 2000 | -0.13x | CN¥-25.05 Million | CN¥197.38 Million | ▼ -292.2% |
| 1999 | 0.07x | CN¥13.64 Million | CN¥206.51 Million | — |